Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2200]

Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly...

Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain

$Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )$

Study shows that there is slower cancer drug approval in Europe

Dr Mark Lythgoe - Imperial College London, London, UK

Study shows that there is slower cancer drug approval in Europe ( Dr Mark Lythgoe - Imperial College London, London, UK )

War in Ukraine: Global cancer aid to support refugees

Dr Horia Vulpe , Dr Ruslan Baltaga

War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )

War in Ukraine: The International Brain Tumour Alliance's response to aiding...

Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance

War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is...

Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Glofitamab induces durable complete remissions in patients with relapsed large...

Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy...

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

More from ecancer